Go to the page content
Obesity

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Locations

United States

Start date

02/02/2026

Identifiers

Trial ID NN9559-8568,
NCT number NCT07395687,
Eudract number Not Available

Summary

The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.

Trial Overview:

Condition

Overweight

Obesity

Treatment

DRUG: UBT251

DRUG: Placebo

Study type

INTERVENTIONAL

Trial duration

Feb 02 2026 - Feb 18 2027

Participants

333

Phase

II

Are you eligible?

Gender

Male and female

Age

18 to 65 years old

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.